Yan Zhiqiang, Wang Jiang, Dong Qiufeng, Zhu Lian, Lin Wei, Jiang Xiaofan
Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Front Surg. 2022 Oct 5;9:937556. doi: 10.3389/fsurg.2022.937556. eCollection 2022.
Glioma originates from glial cells in the brain and is the most common primary intracranial tumor. This study intends to use a retrospective analysis to explore the factors that can predict tumor progression in adult low-grade gliomas, namely WHO II grade patients, within 5 years after surgery.
Patients with WHO grade II glioma who were surgically treated in our hospital from February 2011 to May 2017 were included. According to the inclusion and exclusion criteria, 252 patients were included in the final analysis. According to the results of the 5-year follow-up (including survival and imaging review results), patients were divided into progression-free group and progression group. Univariate and multivariate analysis were conducted to investigate the related factors of tumor progression during the 5-year follow-up.
The results of the 5-year follow-up showed that 111 (44.0%) cases had no progress (progression free group, PFG), 141 (56.0%) cases had progress (progression group, PG), of which 43 (30.5%) cases were operated again, 37 cases (26.2%) received non-surgical treatments. There were 26 (10.3%) all-cause deaths, and 21 (8.3%) tumor-related deaths. Univariate and multivariate analysis showed that age >45 years old (OR = 1.35, 95% CI, 1.07-3.19, = 0.027), partial tumor resection (OR = 1.66, 95% CI, 1.15-3.64, = 0.031), tumor diameter >3 cm (OR = 1.52, 95% CI, 1.14-4.06, = 0.017) and no radiotherapy (OR = 1.37, 95% CI, 1.12-2.44, = 0.039) were independent predictors of the progression of tumor during the 5-year follow-up period.
Age >45 years old, partial tumor resection, tumor diameter >3 cm, no radiotherapy are predictors for tumor progression for glioma patients after surgery.
胶质瘤起源于脑内的胶质细胞,是最常见的原发性颅内肿瘤。本研究旨在采用回顾性分析方法,探讨可预测成人低级别胶质瘤(即世界卫生组织II级患者)术后5年内肿瘤进展的因素。
纳入2011年2月至2017年5月在我院接受手术治疗的世界卫生组织II级胶质瘤患者。根据纳入和排除标准,最终纳入252例患者进行分析。根据5年随访结果(包括生存情况和影像学复查结果),将患者分为无进展组和进展组。进行单因素和多因素分析,以研究5年随访期间肿瘤进展的相关因素。
5年随访结果显示,111例(44.0%)无进展(无进展组,PFG),141例(56.0%)有进展(进展组,PG),其中43例(30.5%)再次手术,37例(26.2%)接受非手术治疗。全因死亡26例(10.3%),肿瘤相关死亡21例(8.3%)。单因素和多因素分析显示,年龄>45岁(OR = 1.35,95%CI,1.07 - 3.19,P = 0.027)、肿瘤部分切除(OR = 1.66,95%CI,1.15 - 3.64,P = 0.